Cardiovascular disease (CVD) is a major cause of mortality in Type 1 diabetes (T1D). Studies suggest that autoimmunity may influence CVD development in T1D. We created a novel T1D-CVD mouse model by deleting ApoE via CRISPR/Cas9 editing in nonobese diabetic (ApoE-/-/NOD) mice, an autoimmune T1D model, and observed that both diabetic and nondiabetic ApoE-/-/NOD mice showed autoimmune insulitis and greater atherosclerotic lipid deposition and plaque formation compared to CongApoE-/‘- wild type (WT) mice. Plasma studies with autoantigen proteomic microarray from people with long-duration T1D>50 years (“Medalists”), identified potential autoantibodies (AAb) targeting antigens in aortic plaques, which correlated to coronary artery calcium (CAC). One protein, nuclear factor-KB inhibitor beta (NFKBIB, p=0.0017), was higher in plasma of Medalists positive for HLA T1D risk alleles (HLA+) compared to HLA(-) Medalists. To quantify circulating anti-NFKBIB in Medalist samples, we developed an immunoassay using novel electrochemiluminescence technology. Our findings showed higher anti-NFKBIB AAb in HLA(+) versus HLA(-) Medalists. Moreover, in the HLA(+) group, higher anti-NFKBIB AAb was seen in those with CVD. To corroborate these findings from Medalist patients, we analyzed plasma from ApoE-/-/NOD mice with autoimmune T1D, as well as control nondiabetic CongApoE/NOD mice. Immunoblot analysis showed that only isolated IgG from plasma of ApoE-/-/NOD mice detected NFKBIB in aortic lysates and/or purified recombinant NFKBIB protein in a concentration-dependent manner, relative to IgG from control mice. Flow cytometry analysis of immunocytes revealed twofold increases in blood and para-aortic B- (CD19+, p=0.012) and T-cell (CD4+, p=0.008) populations of ApoE-/-/NOD mice compared to WT mice. These suggest that anti-NFKBIB AAb is a novel AAb present in people and mouse models with T1D and atherosclerosis, and may contribute to CVD development in T1D.

Disclosure

K. Park: None. L. Pham: None. Q. Li: None. M. Yu: None. J. Fu: None. S. Jangolla: None. I. Wu: None. G.L. King: None.

Funding

5R01HL161864-02, Beatson foundation #5R01HL161864-02

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.